[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370714-105":59,"doc-detail-370714-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","diagnostic-and-therapeutic-advances-for-her2-expressing-or-amplified-gynecologic-cancers","Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers","","HER2-targeting therapies have established roles in breast, gastric, and lung cancers, while accumulating evidence supports their relevance in gynecologic malignancies. Despite variability in HER2 testing methods, a substantial fraction of endometrial, ovarian, cervical, and vulvar cancers overexpress HER2, motivating HER2-directed treatment strategies including tyrosine kinase inhibitors, antibody-drug conjugates, and immune-stimulating antibodies. The work also addresses diagnostic testing approaches, scoring consensus, and resistance mechanisms.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/diagnostic-and-therapeutic-advances-for-her2-expressing-or-amplified-gynecologic-cancers/370714/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/diagnostic-and-therapeutic-advances-for-her2-expressing-or-amplified-gynecologic-cancers/370714.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are HER2-targeting therapies considered relevant to gynecologic cancers?","Question",{"text":113,"@type":114},"Evidence indicates that many endometrial, ovarian, cervical, and vulvar cancers overexpress HER2, supporting HER2-directed therapeutic approaches in these malignancies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Is there a single, widely accepted HER2 testing criterion for gynecologic cancers?",{"text":118,"@type":114},"No. Multiple scoring systems have been used, and insufficient evidence supports superiority of any specific HER2 testing modality (IHC, ISH, or NGS) or a specific IHC scoring criterion for predicting response.",{"name":120,"@type":111,"acceptedAnswer":121},"What HER2 IHC scoring consensus is emerging for different gynecologic tumors?",{"text":122,"@type":114},"Emerging pathology consensus recommends using the 2016 ASCO/CAP gastric criteria for HER2 IHC, while another consensus recommends modified 2007 ASCO/CAP breast criteria for uterine serous carcinoma.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370714,1790449691,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Gynecol Oncol. Author manuscript; available in PMC 2025 July 11. |\n| --- | --- |\n\nPublished in final edited form as:  \nGynecol Oncol. 2025 April ; 195: 152–164. doi:10.1016/j.ygyno.2025.03.011 .  \nDiagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers  \nElizabeth K. Leea,* , David L. Kolinb, Ursula A. Matulonisa, Britt K. Ericksonca Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America  \nb Department of Pathology, Brigham & Women’s Hospital, Boston, MA, United States of America c Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Minnesota, Minneapolis, MN, United States of America  \nAbstract  \nHER2-targeting therapies are well-described in breast, gastric, and lung cancers, however accumulating data supports a role for HER2-targeted therapies in gynecologic cancers. Despite varied methodologies for HER2 testing, evidence supports that a substantial proportion of endometrial, ovarian, cervical, and vulvar cancers overexpress HER2 . This underscores the rationale for HER2-targeted therapies in these malignancies, including the use of HER2-directed tyrosine kinase inhibitors, antibody-drug conjugates, and immune-stimulating antibody  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Corresponding author at: Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States of America.  \n[elizabethk_lee@dfci.harvard.edu](elizabethk_lee@dfci.harvard.edu) (E.K. Lee).  \nCRediT authorship contribution statement  \nElizabeth K. Lee: Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. David L. Kolin: Writing – review & editing, Writing – original draft, Formal analysis, Data curation. Ursula A. Matulonis: Writing – review &  \nediting, Writing – original draft. Britt K. Erickson: Writing – review & editing, Writing – original draft.  \nDeclaration of competing interest  \nEKL: Grant from NCI Ovarian Cancer SPORE; travel support from GOG/NRG; participation in advisory board for Aadi Bioscience.  \nDLK: Stock options in Abbott Laboratories, Alcon Inc., Becton Dickinson, Novartis, Pfizer, UnitedHealth Group.  \nUAM: Honoraria from Med Learning Group; participation in advisory boards for Symphogen, Alkermes, Tango Therapeutics, ProfoundBio, Eisai, Eli Lilly, Novartis, Curelab, Immunogen, Allarity, Nextcure, Ovarian Cancer Research Alliance, Rivkin Foundation, Pfizer.  \nBKE: R50 grants from NCI and GOG Foundation scholar award; consulting for Gilead; honoraria from Kaplan, Curio Science, participation in advisory boards for AstraZeneca, Merck, GSK.  \nCurrently, there is insufficient evidence showing superiority of a specific ERBB2/HER2 testing modality (IHC, ISH, NGS), nor of a specific HER2 IHC scoring criteria, in predicting response to HER2-based therapies.  \nTesting HER2 in gynecologic cancers at initial diagnosis is recommended if participation in a clinical trial is under consideration. Tumors from patients with recurrent gynecologic cancer should undergo HER2 testing, given the accelerated FDA approval ofT-DXd for previously-treated, recurrent HER2 IHC 3+ solid tumors.  \nEmerging pathology consensus is that HER2 IHC be scored using the 2016 ASCO/CAP gastric criteria, based on the DESTINYPanTumor02 trial informing on the accelerated FDA approval.  \nTumors from patients with advanced stage and recurrent uterine serous carcinoma should be tested for HER2 .  \nPathology consensus is that HER2 IHC be scored using the modified 2007 ASCO/CAP breast criteria, based on the phase 2 trial of carboplatin/paclitaxel +/− trastuzumab in USC (Fader et al), leading to incorporation of this regimen within ","cbCaifBDjUVysasr","https://ap.wps.com/l/cbCaifBDjUVysasr","pdf",1657260,29,"English","# Abstract\n## Keywords\n## 1. Introduction\n## 2. Diagnostic testing for HER2 in gynecologic cancers","[{\"question\":\"Why are HER2-targeting therapies considered relevant to gynecologic cancers?\",\"answer\":\"Evidence indicates that many endometrial, ovarian, cervical, and vulvar cancers overexpress HER2, supporting HER2-directed therapeutic approaches in these malignancies.\"},{\"question\":\"Is there a single, widely accepted HER2 testing criterion for gynecologic cancers?\",\"answer\":\"No. Multiple scoring systems have been used, and insufficient evidence supports superiority of any specific HER2 testing modality (IHC, ISH, or NGS) or a specific IHC scoring criterion for predicting response.\"},{\"question\":\"What HER2 IHC scoring consensus is emerging for different gynecologic tumors?\",\"answer\":\"Emerging pathology consensus recommends using the 2016 ASCO/CAP gastric criteria for HER2 IHC, while another consensus recommends modified 2007 ASCO/CAP breast criteria for uterine serous carcinoma.\"}]","Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers | PDF",1790190045,73]